Neurologist Dr. Elijah Stommel explains that he sees two newly diagnosed ALS patients each week and that each case is unique. In Andy’s case, the first indications of the disease appeared in his limbs. Andy had the genetic form of the disease and both of his siblings passed away from ALS. Dr. Stommel explains that ALS…
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Dec. 20, 2017 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide a corporate overview at the 10th Annual Biotech Showcase, being held on January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco, California. more at: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2323496
IQVIA, the recently formed merger of IMS Health and Quintiles, just announced publication of ““Heralding the Era of Human Data Science”. “Human Data Science is a revolutionary new way to harness advances in technology, analytics and, above all, human ingenuity to help you pursue improvements in health outcomes.” More at: https://www.iqvia.com/~/media/IQVIA/PDFS/AccessPoint/A1-from-IQVIA-AccessPoint-14-ORB1824_F.pdf
Dec 13, 2017 By Sandy Chase Applied Clinical Trials Like so many of my colleagues in the world of clinical patient recruitment and retention, I spend a lot of time contemplating data points. Key performance indicators. Screen fail rates. Randomization numbers. Retention rates (and their dubious sibling, drop-out rates). I’ve learned that data points which surface predictably in recap decks, often paint an unfinished picture. Of all…
Tagged biotechDate:December 15, 2017 Source:Columbia University Medical Center Summary:Investigators have been trying to understand why and have recently found how an individual’s own genes can play a role in the response to the immunotherapy drugs. Cancer cells arise when DNA is mutated, and these cells should be recognized as “foreign” by the immune system. However, cancer…
Dr. Laurie Glimcher, President and CEO of the Dana-Faber Cancer Institute (DFCI), is justifiably concerned that Congress is not providing sufficient funding for the NIH. She expressed her worries last week at the Forbes Healthcare Summit in NYC saying that “places like the DFCI are where new drugs are born” and that “decreased funding to…
BrainStorm Cell Therapeutics released new data on potential biomarkers from its Phase 2 trial investigating NurOwn, the company’s cell therapy for amyotrophic lateral sclerosis (ALS), at the International Symposium on ALS/MND meeting held in Boston last week. Both these findings and an ongoing Phase 3 trial, now recruiting patients in the U.S., were discussed in greater detail with Ralph…
The Conference Forum was delighted to present the 7th annual DPharm: Disruptive Innovations to Advance Clinical Trials conference, with a full day dedicated to Mobile in Clinical Trials on Wednesday September 6. Mark your calendars, DPharm 2018 will take place, September 25-26 in Boston. We are dedicated to presenting the annual event that the life science industry can rely on for the latest thinking…
Will you be at the J.P. Morgan Healthcare Conference in January? If so, I hope you’ll join us for the FierceBiotech Executive Breakfast, Get Good Science and the Money will Follow on January 9th at the Fairmont Hotel in San Francisco. The event will run from 7:00AM-8:30AM and will include a full buffet breakfast. Biotech…
